» Articles » PMID: 18222548

Prophylactic and Therapeutic Intervention of Punta Toro Virus (Phlebovirus, Bunyaviridae) Infection in Hamsters with Interferon Alfacon-1

Overview
Journal Antiviral Res
Publisher Elsevier
Date 2008 Jan 29
PMID 18222548
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Punta Toro virus (PTV) is a member of the Bunyaviridae family, genus Phlebovirus, related to the highly pathogenic Rift Valley fever virus (RVFV). It produces a disease in hamsters that models severe Rift Valley fever (RVF) in humans. The recent outbreak of RVF in Kenya stresses the need to identify prophylactic and therapeutic measures for preventing and treating severe forms of disease. To this end, interferon (IFN) alfacon-1 (consensus IFN-alpha) was evaluated in cell culture against RVFV and PTV, and in the hamster PTV infection model. Survival outcome following treatment initiated pre- and post-virus challenge and the suppression of viral burden and liver disease in infected hamsters was determined. Pre-treatment of cell cultures with IFN alfacon-1 induced marked antiviral activity against both viruses. Intraperitoneal treatment of hamsters initiated 4 h prior to infection with PTV was highly protective and greatly limited liver disease and systemic and liver viral burden. Complete protection from a highly lethal challenge dose was afforded by treatment initiated 36 h following viral inoculation. Although efficacy was much reduced, IFN alfacon-1 therapy was still beneficial when started as late as 3-5 days post-virus exposure. These studies suggest that IFN alfacon-1 may be an effective treatment for early intervention following infection with RVFV.

Citing Articles

Rift Valley fever virus infection in golden Syrian hamsters.

Scharton D, Van Wettere A, Bailey K, Vest Z, Westover J, Siddharthan V PLoS One. 2015; 10(1):e0116722.

PMID: 25607955 PMC: 4301868. DOI: 10.1371/journal.pone.0116722.


Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201).

Gowen B, Ennis J, Sefing E, Wong M, Jung K, Turner J Antimicrob Agents Chemother. 2012; 56(8):4168-74.

PMID: 22615273 PMC: 3421622. DOI: 10.1128/AAC.00376-12.


Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.

Narayanan A, Bailey C, Kashanchi F, Kehn-Hall K Expert Opin Investig Drugs. 2011; 20(2):239-54.

PMID: 21235430 PMC: 9476113. DOI: 10.1517/13543784.2011.547852.


Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models.

Gowen B, Wong M, Jung K, Smee D, Morrey J, Furuta Y Antiviral Res. 2009; 86(2):121-7.

PMID: 19874853 PMC: 3008316. DOI: 10.1016/j.antiviral.2009.10.015.


Punta Toro virus (Bunyaviridae, Phlebovirus) infection in mice: strain differences in pathogenesis and host interferon response.

Mendenhall M, Wong M, Skirpstunas R, Morrey J, Gowen B Virology. 2009; 395(1):143-51.

PMID: 19783024 PMC: 2783532. DOI: 10.1016/j.virol.2009.09.003.

References
1.
Canonico P, KENDE M, Luscri B, Huggins J . In-vivo activity of antivirals against exotic RNA viral infections. J Antimicrob Chemother. 1984; 14 Suppl A:27-41. DOI: 10.1093/jac/14.suppl_a.27. View

2.
Blatt L, Davis J, Klein S, Taylor M . The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996; 16(7):489-99. DOI: 10.1089/jir.1996.16.489. View

3.
Echevarria J, de Ory F, Guisasola M, Sanchez-Seco M, Tenorio A, Lozano A . Acute meningitis due to Toscana virus infection among patients from both the Spanish Mediterranean region and the region of Madrid. J Clin Virol. 2003; 26(1):79-84. DOI: 10.1016/s1386-6532(02)00041-0. View

4.
Charrel R, Gallian P, Navarro-Mari J, Nicoletti L, Papa A, Sanchez-Seco M . Emergence of Toscana virus in Europe. Emerg Infect Dis. 2005; 11(11):1657-63. PMC: 3367371. DOI: 10.3201/eid1111.050869. View

5.
Gerdes G . Rift valley fever. Vet Clin North Am Food Anim Pract. 2002; 18(3):549-55. DOI: 10.1016/s0749-0720(02)00029-4. View